GASTROINTESTINAL TRACT MULTIPLE LYMPHOMATOUS POLYPOSIS PRESENTED AS MANTLE CELL LYMPHOMA

Abstract

Aims: Mantle cell lymphoma is a mature B cell non-Hodgkin lymphoma which may be presented with the involvement of the gastrointestinal tract as multiple lymphomatous polyposis. The aim of this case report is to increase the awareness of including lymphomatoid polyposis as an entity in the differential diagnosis of multiple polyposis of the gastrointestinal tract. Case Report: A 69-year-old male patient was admitted to the Trakya University Emergency Department with acute abdominal pain. His cli-nical findings were anorexia that started 3-4 months ago together with constipation and nausea causing him to lose 10-15 kg in 7-8 months, with denial of other parameters of B-symptoms (fevers and night sweats). Endoscopic biopsies that were taken from bulbus and duodenum were investigated and he was diagnosed with mantle cell lymphoma. The patient went through an ileoce-cal resection due to his intussusception that caused abdominal pain in the first place. Conclusion: Although being an infrequent disease, gastrointestinal lymphomatoid polyposis should be an entity comprised in differential diagnosis for multiple polyposis of the gastrointestinal tract. On the other hand, there is still not a therapeutic protocol with a definitive cure for gastrointestinal tract mantle cell lymphoma. Elderly patients in high risk group such as our patient should be given treatment by taking their conditions into consideration. Keywords: Mantle cell lymphoma, polyp, non-Hodgkin lymphoma

Keywords

• Mantle cell lymphoma,polyp,non-Hodgkin lymphoma

References

1. 1. Swerdlow SH, Campo E, Harris NL et al. WHO classificati-on of tumours of haematopoietic and lymphoid tissues. Blood 2011;117:5019–32.
2. 2. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extra-nodal lymphomas. Cancer 1972;29:252–60.
3. 3. Cheah CY, George A, Gine E et al. Central nervous system invol-vement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013;24:2119-23.
4. 4. Ferrer A, Salaverria I, Bosch F et al. Leukemic involvements is a common feature in mantle cell lymphoma. Cancer 2007;109:2473-80.
5. 5. Romaguera JE, Mederious LJ, Hagemeister FB et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003;97:586-91.
6. 6. Ruskone-Fourmestraux A, Delmer A, Lavergne A et al. Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Gastroenterology 1997;112:7-16.
7. 7. Dawsey SP, Gregory JA, Brwon AW et al. Asymptomatic multiple lymphomatous polyposis identified during staging bidirectional en-doscopy of mantle cell lymphoma. Case Rep Oncol 2016;9(3):661–5.
8. 8. Cornes JS. Multiple lymphomatous polyposis of the gastrointesti-nal tract. Cancer 1961;14:249–57.

9. 9. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1.
10. 10. Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blo-od 2008;111:558–65.
11. 11. Oken MM, Creech RH, Tormey DC et al. Toxicity And Respon-se Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
12. 12. Drillenburg P, Van der Voort R, Koopman G et al. Preferenti-al expression of the mucosal homing receptor integrin alpha 4 beta 7 in gastrointestinal non-Hodgkin’s lymphomas. Am J Pathol 1997;150:919–27.
13. 13. Geissmann F, Ruskoné-Fourmestraux A, Hermine O et al. Homing receptor alpha 4 beta 7 integrin expression predicts di-gestive tract involvement in mantle cell lymphoma. Am J Pathol 1998;153:1701–5.
14. 14. Vogt N, Dai B, Erdmann T et al. The molecular pathogenesis of mantle cell lymphoma. Leuk Lymphoma 2017;58(7):1530-7.
15. 15. Geisler CH, Kolstad A, Laurell A et al. Long-term progressi-on-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a non-randomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-93.
16. 16. Albertsson-Lindblad A, Kolstad A, Laurell A et al. Lenalidomi-de-bendamustine-rituximab in patients older than 65 years with unt-reated mantle cell lymphoma. Blood 2016;128:1814-20.
17. 17. Gressin R, Daguindau N, Tempescul A et al. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Ha-ematologica 2019;104:138-46.